Continued growth in the licensing business and in our product portfolio Second quarter (April-June 2022) Revenues amounted to SEK 59.9 (46.0) million, an increase of 30%. Adjusted for currency, revenues increased by 13%. EBITDA amounted to SEK -3.8 (1.8) million, with an EBITDA margin of -6.4% (4.0). Operating profit/loss amounted to SEK -14.8...
Bactiguard Holding AB (publ) publishes the interim report for the second quarter on Thursday July 14, 2022 at 8:00 CET.In connection with this, an audiocast for investors, analysts and media will be held at 11:00 CET on July 14. CEO Anders Göransson and CFO Carin Jakobson will present the interim report and answer questions. The report and a...
Bactiguard has been informed that the European Patent Office (EPO) intends to grant a European patent for Bactiguard’s infection prevention technology. The new patent, which is the third generation, will provide extensive worldwide protection for the Bactiguard technology until 2039. - We are very pleased that the EPO has confirmed that the new...
The Board of Directors in Bactiguard Holding AB (publ) has been informed by the company’s main owners, Christian Kinch, Thomas von Koch and Jan Ståhlberg, that senior management and key employees in Bactiguard have acquired call options in Bactiguard issued by the three main owners, comprising shares corresponding to 4 per cent of all shares...
At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 29 April 2022, the following resolutions were made: The AGM adopted the income statements and balance sheets for 2021 and decided that no dividend for the financial year 2021 will be paid. Retained earnings and the company's result for the year will be carried forward. The Board...
A broader and stronger licensing business strengthens our position in infection prevention First quarter (January-March 2022) Revenues amounted to SEK 55.2 (41.8) million, an increase of 32%, mainly through higher licensing revenues. Adjusted for currency the increase was 23%. EBITDA amounted to SEK -4.0 (1.9) million with an EBITDA-margin of -7%...
Bactiguard Holding AB (publ) publishes the interim report for the first quarter of 2022 on Wednesday, April 27, 2022, at 08.00 and holds the Annual General Meeting via postal vote on April 29, 2022.In connection with this, an audiocast for shareholders, investors and analysts will be held at 11:00 CET on April 27. CEO Anders...
Bactiguard today entered an agreement to initiate a global development partnership with Dentsply Sirona in the dental field, a new application area for the Bactiguard technology. The initial development phase, which is expected to last approximately one year, can generate USD 0.9 million in development and milestone related revenues for...
The annual report for Bactiguard Holding AB (publ) 2021 is now available at www.bactiguard.com. The annual report is available as a downloadable PDF document in both Swedish and English. A printed version of the report will be available from April 29 and can be ordered by sending an email to: info@bactiguard.com. This information is...
The shareholders of Bactiguard Holding AB (publ), company reg. no. 556822-1187 (“Bactiguard”), are hereby given notice to attend the Annual General Meeting (AGM) to be held on Friday, 29 April 2022. Due to the continued uncertainty about the Covid-19 pandemic, the Board of Directors has decided that the AGM will be conducted without physical...
Bactiguard Holding AB (publ) has appointed Carin Jakobson, who has many years of experience as CFO of listed companies and a background in the medtech and pharmaceutical industry, as Chief Financial Officer. Carin Jakobson, who is currently CFO of the Rolling Optics Group, will take up her new position at Bactiguard in June 2022 and report to...
The hospitals in Ukraine are in urgent need of medical devices to manage the health care challenges related to the outbreak of war. Through a network of doctors at the Karolinska University hospital, supported by the Ukrainian Embassy, Bactiguard is providing intensive care products that Ukrainian healthcare has asked for and need. “It is...
In previous press releases regarding the year-end report for 2021, incorrect information related to "Cash flow from operating activities" has been reported. Correction is made with this press release and the correct PDF is attached for Bactiguard Holding AB's (publ) year-end report 2021. Investments for future sales growth impacted profitability...
Investments for future sales growth impacted profitability Fourth quarter (October-December 2021) Revenues amounted to SEK 46.1 (55.6) million, a decrease of 17%, primarily due to lower license revenue. Adjusted for currency effects revenues decreased by 22%. EBITDA amounted to SEK -12.1 (4.9) million with an EBITDA margin of -26% (9%). Operating...
Bactiguard presents new long-term financial targets in connection with the year-end report for 2021. The new financial targets relate to growth and profitability, with annual revenues of at least 1 billion SEK and annual EBITDA of at least 400 million SEK in 2026. "With Bactiguard's unique technology for infection prevention, scalable business...
Following the announcement of the expanded partnership with Zimmer Biomet, Bactiguard has decided to publish the year-end report for 2021 tonight at 23.00 CET, instead of on Thursday February 10, as earlier announced. An audiocasted presentation will take place on Wednesday February 9 at 15.00 CET. Bactiguard's CEO Anders Göransson and CFO...
Bactiguard and Zimmer Biomet have today agreed to expand the global license partnership, that was initiated in 2019, to cover multiple product segments. The extended exclusive license agreement covers implants for joint reconstruction (hips and knees), sports medicine, craniomaxillofacial and thoracic applications. It includes license and...
The VITAL study, by Professor Pierre Damas and his team, is now published in the well renowned journal Annals of Intensive Care. The study shows a 53% reduction of ventilator-associated pneumonia with Bactiguard’s endotracheal tube. It was presented for the first time at the European Society of Intensive Care congress (ESICM) in October 2021....